Amanda Martinez Lyra

Prof. Amanda Martinez Lyra

UEPG
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2020 in Molecules
Verified
Journal Article
Open access
PDF file
LRLoanda Cabral Rudnik
Loanda Cabral Rudnik
PFPaulo Vitor Farago
Paulo Vitor Farago
JMJane Manfron
Jane Manfron
ALAmanda Martinez Lyra
Amanda Martinez Lyra
FBFernanda Malaquias Barboza
Fernanda Malaquias Barboza
SZSandra Maria Warumby Zanin
Sandra Maria Warumby Zanin
Background: As part of the efforts to find natural alternatives for cancer treatment and to overcome the barriers of cellular resistance to chemotherapeutic agents, polymeric nanocapsules containing curcumin and/or methotrexate were prepared by an interfacial deposition of preformed polymer method. Methods: Physicochemical properties, drug release experiments and in vitro cytotoxicity of these nanocapsules were performed against the Calu-3 lung cancer cell line. Results: The colloidal suspensions of nanocapsules showed suitable size (287 to 325 nm), negative charge (−33 to −41 mV) and high encapsulation efficiency (82.4 to 99.4%). Spherical particles at nanoscale dimensions were observed by scanning electron microscopy. X-ray diffraction analysis indicated that nanocapsules exhibited a non-crystalline pattern with a remarkable decrease of crystalline peaks of the raw materials. Fourier-transform infrared spectra demonstrated no chemical bond between the drug(s) and polymers. Drug release experiments evidenced a controlled release pattern with no burst effect for nanocapsules containing curcumin and/or methotrexate. The nanoformulation containing curcumin and methotrexate (NCUR/MTX-2) statistically decreased the cell viability of Calu-3. The fluorescence and morphological analyses presented a predominance of early apoptosis and late apoptosis as the main death mechanisms for Calu-3. Conclusions: Curcumin and methotrexate co-loaded nanocapsules can be further used as a novel therapeutic strategy for treating non-small-cell lung cancer.

26 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
GCGuilherme dos Anjos Camargo
Guilherme dos Anjos Camargo
Leandro FerreiraLeandro Ferreira
Leandro Ferreira
DSDiego José Schebelski
Diego José Schebelski
ALAmanda Martinez Lyra
Amanda Martinez Lyra
FBFernanda Malaquias Barboza
Fernanda Malaquias Barboza
PFPaulo Vitor Farago
Paulo Vitor Farago
Background: Tacrolimus (TAC) is a drug of natural origin used in conventional topical dosage forms to control atopic dermatitis. However, direct application of the drug often causes adverse side effects in some patients. Hence, drug nanoencapsulation could be used as an improved novel therapy to mitigate the adverse effects and enhance bioavailability of the drug. Methods: Physicochemical properties, in vitro drug release experiments, and in vivo anti-inflammatory activity studies were performed. Results: TAC-loaded nanocapsules were successfully prepared by the interfacial deposition of preformed polymer using poly(ε-caprolactone) (PCL). The nanoparticulate systems presented a spherical shape with a smooth and regular surface, adequate diameter (226 to 250 nm), polydispersity index below 0.3, and suitable electrical stability (−38 to −42 mV). X-ray diffraction confirmed that the encapsulation method provided mainly the drug molecular dispersion in the nanocapsule oily core. Fourier-transform infrared spectra suggested that nanoencapsulation did not result in chemical bonds between drug and polymer. In vitro drug dissolution experiments showed a controlled release with a slight initial burst. The release kinetics showed zero-order kinetics. As per the Korsmeyer–Peppas model, anomalous transport features were observed. TAC-loaded PCL nanocapsules exhibited excellent anti-inflammatory activity when compared to the free drug. Conclusions: TAC-loaded PCL nanocapsules can be suitably used as a novel nano-based dosage form to control atopic dermatitis.

1 January 2020 in Brazilian Archives of Biology and Technology
Verified
Journal Article
Open access
PDF file
LRLoanda Aparecida Cabral Rudnik
Loanda Aparecida Cabral Rudnik
ALAmanda Martinez Lyra
Amanda Martinez Lyra
FBFernanda Malaquias Barboza
Fernanda Malaquias Barboza
TKTraudi Klein
Traudi Klein
CKCarla Cristine Kanunfre
Carla Cristine Kanunfre
Jessica NadalJessica Nadal
Jessica Nadal
Curcumin (CUR) shows potential use for treating cancer. However, CUR has low solubility and reduced bioavailability, which limit its clinical effect. Therefore, the development of nanocarriers can overcome these problems and can ensure the desired pharmacological effect. In addition, it is mandatory to prove the quality, the efficacy, and the safety for a novel nanomedicine to be approved. In that sense, this paper aimed (a) to prepare CUR-loaded polyethylene glycol-poly(ε-caprolactone) nanocapsules; (b) to validate an analytical method by high performance liquid chromatography (HPLC) for quantifying CUR in these nanoformulations; (c) to evaluate the physicochemical stability of these formulations; and to investigate their cytotoxicity on NIH-3T3 mouse fibroblast cells. The HPLC method was specific to CUR in the loaded nanocapsules, linear (r = 0.9994) in a range of 10.0 to 90.0 µg.mL-1 with limits of detection and quantification of 0.160 and 0.480 µg.mL-1, respectively. Precision was demonstrated by a relative standard deviation lower than 5%. Suitable accuracy (102.37 ± 0.92%) was obtained. Values of pH, particle size, polydispersity index, and zeta potential presented no statistical difference (p > 0.05) for CUR-loaded nanoparticles. No cytotoxicity was observed against NIH-3T3 mouse embryo fibroblast cell line using both the tetrazolium salt and sulforhodamine B assays. In conclusion, a simple and inexpensive HPLC method was validated for the CUR quantification in the suspensions of nanocapsules. The obtained polymeric nanocapsules containing CUR showed suitable results for all the performed assays and can be further investigated as a feasible novel approach for cancer treatment.

1 December 2021 in Journal of Nanoscience and Nanotechnology
Verified
Journal Article
Closed access
GCGuilherme dos Anjos Camargo
Guilherme dos Anjos Camargo
ALAmanda Martinez Lyra
Amanda Martinez Lyra
FBFernanda M. Barboza
Fernanda M. Barboza
BFBarbara C. Fiorin
Barbara C. Fiorin
FBFlávio Luís Beltrame
Flávio Luís Beltrame
PFPaulo Vitor Farago
Paulo Vitor Farago
The aim of this paper was to use chromatographic tools for validating an analytical method for the tacrolimus (TAC) determination in polymeric nanocapsules and for identifying the drug degradation products after alkaline stress. A rapid Ultra-High-Performance Liquid Chromatography coupled with photo-diode array (UHPLC-PDA) method was successfully performed using the following chromatographic conditions: the Shimadzu Shim-pack XR-ODS III C18 column (100 mm×2.00 mm, 2.2 μm), the mobile phase consisting of methanol and acidified ultrapure water (89:11 v/v), the flow rate of 0.55 mL·min−1, and the ultraviolet (UV) detection at 235 nm. This method was validated as per International Council for Harmonisation (ICH) guidelines. In addition, a TAC forced degradation assay was carried out after alkaline stress and its degradation products were investigated using Liquid Chromatography coupled tandem mass spectroscopy (LC-MS/MS). The calibration curve was linear in the range of 100.0–300.0 μg·mL−1 (r >0.9999). Accuracy was confirmed by the TAC recovery of 96.55 to 98.19%. Precision (intraday and interday) were demonstrated by relative standard deviation lower than 0.89% and 3.25%, respectively. Selectivity and robustness were also proved. The method developed it was successfully applied to quantify TAC from polymeric nanocapsules, showing a high loading efficiency rate (>96.47%). The main drug degradation product observed in a multiple reaction monitoring (MRM) experiment was m/z 844, confirming the susceptibility of TAC under alkaline conditions; this finding was first time described.

1 January 2023 in Brazilian Archives of Biology and Technology
Verified
Journal Article
Open access
JRJuliana Parente Menezes Ribeiro
Juliana Parente Menezes Ribeiro
DSDiego José Schebelski
Diego José Schebelski
ALAmanda Martinez Lyra
Amanda Martinez Lyra
GCGuilherme dos Anjos Camargo
Guilherme dos Anjos Camargo
Jessica NadalJessica Nadal
Jessica Nadal
PFPaulo Vitor Farago
Paulo Vitor Farago

1 August 2021 in Brazilian Journal of Development
Verified
Journal Article
Closed access
PDF file
AMAna Cláudia de Ávila Martins
Ana Cláudia de Ávila Martins
ALAmanda Martinez Lyra
Amanda Martinez Lyra
ALAndrea Franco de Lima
Andrea Franco de Lima
LZLarissa Aparecida Zadra
Larissa Aparecida Zadra
OHOhanna Crhistine Haile
Ohanna Crhistine Haile
RNRobson Schimandeiro Novak
Robson Schimandeiro Novak
Os exames laboratoriais são de extrema importância para o auxílio em diagnósticos das mais diversas patologias. Sabe-se que um problema ocasionado em coletas com maior frequência é a hemólise. A hemólise é descrita como uma ruptura das hemácias, levando ao extravasamento do seu conteúdo interno, que pode ocorrer por um erro no momento da coleta, no processamento, no transporte ou no armazenamento da amostra. O presente trabalho teve como objetivo, analisar diferentes graus de hemólise em amostras de dosagens de colesterol para verificar qual o impacto do fenômeno na precisão dos resultados, de maneira a prevenir transtornos e gastos com tempo e perca financeira. Para isso, produziu-se um pool de amostras de soros não hemolisados e um pool de sangue total com água deionizada para provocar hemólise. Em seguida foram aliquotados amostras com pool de soro, e a estas, foram adicionadas uma quantidade definida do sangue hemolisado para produzir diferentes graus de hemólise. Os resultados obtidos mostraram que um erro pré-analítico, que parece simples, pode acarretar em diagnósticos errôneos e inconfiabilidade por parte do laboratório.